Literature DB >> 29396610

Arsenic trioxide: insights into its evolution to an anticancer agent.

Maneka Hoonjan1, Vaibhav Jadhav1, Purvi Bhatt2.   

Abstract

Arsenic and its various forms have been in use in ancient Chinese medicine for more than 2000 years. Arsenicals have gained importance for having remedial effects for various diseases from syphilis to cancer thus highlighting its role as a therapeutic agent even though it has been labelled as a potential 'poison'. The ability of arsenic, specifically arsenic trioxide, to treat acute promyelocytic leukaemia has radically changed the perception of this poison and has been the main factor for the re-emergence of this candidate to Western medicine for the treatment of leukaemia and other solid tumours. This review highlights the glorious history of arsenic and its various forms with major emphasis on arsenic trioxide as a therapeutic agent. The mechanism of action, pathogenesis, pharmacokinetic profile, safety concerns, ongoing clinical trials and various new forms of arsenic trioxide are discussed. The review also outlines the therapeutic ability of this drug, discusses the latest developments and recent investigations and potential advancement of arsenic trioxide as nanoformulations that has made it emerge as a potential remedial agent.

Entities:  

Keywords:  Acute promyelocytic leukaemia; Anticancer drug; Arsenic trioxide; Cancer; In silico; Nanotechnology; Solid tumour

Mesh:

Substances:

Year:  2018        PMID: 29396610     DOI: 10.1007/s00775-018-1537-9

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  127 in total

Review 1.  Nanotechnology for the biologist.

Authors:  Scott E McNeil
Journal:  J Leukoc Biol       Date:  2005-05-27       Impact factor: 4.962

Review 2.  Magnetic nanoparticles in MR imaging and drug delivery.

Authors:  Conroy Sun; Jerry S H Lee; Miqin Zhang
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

3.  Notch-1 and notch-4 receptors as prognostic markers in breast cancer.

Authors:  Katharine Yao; Paola Rizzo; Prabha Rajan; Kathy Albain; Karen Rychlik; Sneha Shah; Lucio Miele
Journal:  Int J Surg Pathol       Date:  2010-05-05       Impact factor: 1.271

Review 4.  [Monoclonal antibodies in cancer therapy].

Authors:  K Pfizenmaier; G A Nagel
Journal:  Dtsch Med Wochenschr       Date:  1985-04-19       Impact factor: 0.628

5.  Apoptosis inducing effects of arsenic trioxide on human bladder cancer cell line BIU-87.

Authors:  Q Tong; F Zeng; L Zheng; J Zhao; G Lu
Journal:  Chin Med J (Engl)       Date:  2001-04       Impact factor: 2.628

6.  Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.

Authors:  C R Kumana; W Y Au; N S L Lee; Maybelle Kou; R W M Mak; C W Lam; Y L Kwong
Journal:  Eur J Clin Pharmacol       Date:  2002-10-11       Impact factor: 2.953

Review 7.  How acute promyelocytic leukaemia revived arsenic.

Authors:  Jun Zhu; Zhu Chen; Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

8.  High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice.

Authors:  T Lufkin; D Lohnes; M Mark; A Dierich; P Gorry; M P Gaub; M LeMeur; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.

Authors:  C William Helm; J Christopher States
Journal:  J Ovarian Res       Date:  2009-01-14       Impact factor: 4.234

View more
  29 in total

1.  Natural variation in C. elegans arsenic toxicity is explained by differences in branched chain amino acid metabolism.

Authors:  Stefan Zdraljevic; Bennett William Fox; Christine Strand; Oishika Panda; Francisco J Tenjo; Shannon C Brady; Tim A Crombie; John G Doench; Frank C Schroeder; Erik C Andersen
Journal:  Elife       Date:  2019-04-08       Impact factor: 8.140

2.  Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.

Authors:  Yu Huang; Zhishi Xu; Yinghui Wei; Shunping Han; Xinjun Cai; Danfei Chen
Journal:  AAPS PharmSciTech       Date:  2022-04-11       Impact factor: 3.246

3.  Beyond Cisplatin: Combination Therapy with Arsenic Trioxide.

Authors:  Ðenana Miodragović; Elden P Swindell; Zohra Sattar Waxali; Abraham Bogachkov; Thomas V O'Halloran
Journal:  Inorganica Chim Acta       Date:  2019-07-24       Impact factor: 3.118

4.  Targeted cancer cell delivery of arsenate as a reductively activated prodrug.

Authors:  Daniela Cioloboc; Donald M Kurtz
Journal:  J Biol Inorg Chem       Date:  2020-03-18       Impact factor: 3.358

5.  MARVELD1 attenuates arsenic trioxide-induced apoptosis in liver cancer cells by inhibiting reactive oxygen species production.

Authors:  Wenping Ma; Haiyang Shen; Qian Li; Hao Song; Yanyan Guo; Fangrong Li; Xingang Zhou; Xinwu Guo; Jingdong Shi; Qi Cui; Jinhao Xing; Jinhai Deng; Youtao Yu; Wenjie Liu; Hongshan Zhao
Journal:  Ann Transl Med       Date:  2019-05

6.  Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent.

Authors:  Đenana Miodragović; Antonello Merlino; Elden P Swindell; Abraham Bogachkov; Richard W Ahn; Sara Abuhadba; Giarita Ferraro; Tiziano Marzo; Andrew P Mazar; Luigi Messori; Thomas V O'Halloran
Journal:  J Am Chem Soc       Date:  2019-04-15       Impact factor: 16.383

7.  Arsenic induced redox imbalance triggers the unfolded protein response in the liver of zebrafish.

Authors:  Patrice Delaney; Anjana Ramdas Nair; Catherine Palmer; Nouf Khan; Kirsten C Sadler
Journal:  Toxicol Appl Pharmacol       Date:  2020-11-02       Impact factor: 4.219

Review 8.  Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments.

Authors:  Damiano Cirri; Francesco Bartoli; Alessandro Pratesi; Emma Baglini; Elisabetta Barresi; Tiziano Marzo
Journal:  Biomedicines       Date:  2021-05-04

9.  Salvianolic Acid A Ameliorates Arsenic Trioxide-Induced Cardiotoxicity Through Decreasing Cardiac Mitochondrial Injury and Promotes Its Anticancer Activity.

Authors:  Jing-Yi Zhang; Min Wang; Rui-Ying Wang; Xiao Sun; Yu-Yang Du; Jing-Xue Ye; Gui-Bo Sun; Xiao-Bo Sun
Journal:  Front Pharmacol       Date:  2018-05-09       Impact factor: 5.810

10.  Arsenic trioxide ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice by inducing CD4+ T cell apoptosis.

Authors:  Ke An; Meng-Jiao Xue; Jia-Ying Zhong; Sheng-Nan Yu; Tian-Shu Lan; Zhong-Quan Qi; Jun-Jie Xia
Journal:  J Neuroinflammation       Date:  2020-05-06       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.